- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001981
The Treatment and Natural History of Acromegaly
November 24, 2020 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acromegaly Treatment and Natural History
The purpose of this study is to investigate the treatment and natural history of acromegaly.
We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases.
We will continue to follow patients and recruit new patients for treatment and follow-up.
Blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to acromegaly.
Study Overview
Status
Completed
Conditions
Detailed Description
The purpose of this study is to investigate the treatment and natural history of acromegaly.
We have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases.
We will continue to follow patients and recruit new patients for treatment and follow-up.
Study Type
Observational
Enrollment (Actual)
117
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
The study involved patients who were referred to us and had acromegaly.@@@@@@
Description
- INCLUSION CRITERIA:
Patients will be enrolled who are 18 years of age or over who are referred for care.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients with acromegaly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
resolution of IGF-1 Growth Hormone abnormality
Time Frame: every 6 months & at end of study
|
resolution of IGF-1 abnormality
|
every 6 months & at end of study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Phillip Gorden, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 2, 1991
Primary Completion (Actual)
November 20, 2020
Study Completion (Actual)
November 20, 2020
Study Registration Dates
First Submitted
January 21, 2000
First Submitted That Met QC Criteria
January 21, 2000
First Posted (Estimate)
January 24, 2000
Study Record Updates
Last Update Posted (Actual)
November 27, 2020
Last Update Submitted That Met QC Criteria
November 24, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Musculoskeletal Diseases
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Bone Diseases
- Bone Diseases, Endocrine
- Hyperpituitarism
- Pituitary Diseases
- Pituitary Neoplasms
- Acromegaly
Other Study ID Numbers
- 850082
- 85-DK-0082
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acromegaly
-
Andrea M. IsidoriCompletedAcromegaly CardiomyopathyItaly
-
Samsung Medical CenterNot yet recruitingAcromegaly Due to Pituitary AdenomaKorea, Republic of
-
University of CopenhagenOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaboratorsCompletedAcromegaly Due to Pituitary AdenomaDenmark
-
PfizerRecruiting
-
University Hospital, MontpellierRecruiting
-
Ginkgo Leaf Center for Rare DisordersRecruiting
-
National Taiwan University HospitalRecruiting
-
Cedars-Sinai Medical CenterActive, not recruitingAcromegalyUnited States
-
Camurus ABActive, not recruitingAcromegalyUnited States, Spain, United Kingdom, Germany, Russian Federation, Greece, Hungary, Italy, Poland, Turkey, Serbia
-
Crinetics Pharmaceuticals Inc.Active, not recruitingAcromegalyUnited States, Argentina, Belgium, Brazil, Bulgaria, France, Hungary, Israel, Italy, Peru, Poland, Russian Federation, Serbia, United Kingdom